GlobeNewswire BiotechnologyCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:02:02·⚡ 决策 09-01 22:30:58 +2h28m·56.3 天前
Dianthus Therapeutics宣布参加9月三场投资者会议
事件本身是常规投关日程公告，不改变公司临床资产状态、商业化前景、融资条件或盈利预期，缺少可交易催化。
📄 原文GlobeNewswire Biotechnology↗ 原文
Dianthus Therapeutics to Participate in Three Investor Conferences During September
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-…
不做 Dianthus Therapeutics, Inc.（DNTH.US）
例行投资者会议公告无增量基本面事实，方向与edge均不足，不开仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Dianthus Therapeutics仅宣布将参加三场9月投资者会议并提供部分webcast入口；该类日程公告通常不构成业务状态迁移，正文没有新数据、新合作、新监管节点或财务指引，因此即使核价或扩展研究也难以改变不交易结论。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 后续会议若披露未预告的临床、监管或合作信息，需要作为新事件重新判断。
先例如何影响了这次决策
对本次决策的影响:先例不会改变本次不交易结论。
方向:例行投关会议日程不具备稳定方向性。
涨幅量级:无实质催化，不适合用价格先例校准止盈止损。
形态:未进入先例测算；正文已足以判断为无增量事实。
原文全文
展开原文 · 1,643 字
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in three investor conferences.
Wells Fargo 21st Annual Healthcare Conference:
Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on September 8, 2026.
Citi's 2026 Biopharma Back to School Conference:
Marino Garcia will participate in a fireside chat on Wednesday, September 9, 2026, at 4:20 p.m. ET and host one-on-one investor meetings.
2026 Cantor Global Healthcare Conference:
Marino Garcia will participate in a fireside chat on Thursday, September 10, 2026, at 8:35 a.m. ET and host one-on-one investor meetings.
Webcasts of the presentations at the Citi and Cantor conferences may be accessed under “News and Events” in the
Investors
section of the Dianthus Therapeutics
website
.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit
www.dianthustx.com
and follow us on
LinkedIn
.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
Wells Fargo 21st Annual Healthcare Conference:
Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on September 8, 2026.
Citi's 2026 Biopharma Back to School Conference:
Marino Garcia will participate in a fireside chat on Wednesday, September 9, 2026, at 4:20 p.m. ET and host one-on-one investor meetings.
2026 Cantor Global Healthcare Conference:
Marino Garcia will participate in a fireside chat on Thursday, September 10, 2026, at 8:35 a.m. ET and host one-on-one investor meetings.
Webcasts of the presentations at the Citi and Cantor conferences may be accessed under “News and Events” in the
Investors
section of the Dianthus Therapeutics
website
.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit
www.dianthustx.com
and follow us on
.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。